help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2002-0217
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liang, F.
Right arrow Articles by Gardner, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liang, F.
Right arrow Articles by Gardner, D. G.
Endocrinology Vol. 144, No. 9 4187-4194
Copyright © 2003 by The Endocrine Society

Peroxisome Proliferator Activated Receptor (PPAR){alpha} Agonists Inhibit Hypertrophy of Neonatal Rat Cardiac Myocytes

Faquan Liang1, Feng Wang1, Sumei Zhang and David G. Gardner

Department of Medicine (D.G.D.) and Diabetes Center (F.L., F.W., S.Z., D.G.D.), University of California at San Francisco, San Francisco, California 94143-0540

Address all correspondence and requests for reprints to: David G. Gardner, Diabetes Center, University of California at San Francisco, 1109 HSW, 513 Parnassus Avenue, San Francisco, California 94143-0540. E-mail: gardner{at}itsa.ucsf.edu.

The peroxisome proliferator activated receptors (PPARs) appear to have beneficial effects in the cardiovascular system. PPAR{gamma} has been shown previously to exert an inhibitory effect on cardiac myocyte hypertrophy in vivo and in vitro. Using endothelin to activate the hypertrophic program in neonatal rat cardiac myocytes, we demonstrate that PPAR{alpha} ligands (fenofibrate and WY14,643) suppress hypertrophy-dependent increases in protein synthesis, cell surface area, and sarcomeric organization in vitro. This was accompanied by a decrease in brain natriuretic peptide gene expression, a marker of transcriptional activation in hypertrophy. These effects were equivalent to or greater than those seen with the PPAR{gamma} agonist rosiglitazone. Fenofibrate and rosiglitazone suppressed endothelin stimulation of human brain natriuretic peptide gene promoter activity, and this effect was amplified by cotransfection of PPAR{alpha} and PPAR{gamma} expression vectors, respectively. The fenofibrate-dependent suppression of endothelin’s stimulatory activity was dependent upon promoter sequence positioned between -904 and -40 relative to the transcription start site and did not appear to involve a number of positive and negative regulatory elements that are known to govern transcription of this gene. These findings suggest that PPAR{alpha} ligands could prove to be useful in the management of disorders associated with hypertrophy and remodeling of the myocardium.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
P. J. H. Smeets, B. E. J. Teunissen, A. Planavila, H. de Vogel-van den Bosch, P. H. M. Willemsen, G. J. van der Vusse, and M. van Bilsen
Inflammatory Pathways Are Activated during Cardiomyocyte Hypertrophy and Attenuated by Peroxisome Proliferator-activated Receptors PPAR{alpha} and PPAR{delta}
J. Biol. Chem., October 24, 2008; 283(43): 29109 - 29118.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. P. Alibin, M. A. Kopilas, and H. D. I. Anderson
Suppression of Cardiac Myocyte Hypertrophy by Conjugated Linoleic Acid: ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS {alpha} AND {gamma}
J. Biol. Chem., April 18, 2008; 283(16): 10707 - 10715.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
P. J.H. Smeets, B. E.J. Teunissen, P. H.M. Willemsen, F. A. van Nieuwenhoven, A. E. Brouns, B. J.A. Janssen, J. P.M. Cleutjens, B. Staels, G. J. van der Vusse, and M. van Bilsen
Cardiac hypertrophy is enhanced in PPAR{alpha}-/- mice in response to chronic pressure overload
Cardiovasc Res, April 1, 2008; 78(1): 79 - 89.
[Abstract] [Full Text] [PDF]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
R. Rodriguez-Calvo, L. Serrano, E. Barroso, T. Coll, X. Palomer, A. Camins, R. M. Sanchez, M. Alegret, M. Merlos, M. Pallas, et al.
Peroxisome Proliferator-Activated Receptor {alpha} Down-Regulation Is Associated With Enhanced Ceramide Levels in Age-Associated Cardiac Hypertrophy
J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2007; 62(12): 1326 - 1336.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. G. Gardner, S. Chen, D. J. Glenn, and C. L. Grigsby
Molecular Biology of the Natriuretic Peptide System: Implications for Physiology and Hypertension
Hypertension, March 1, 2007; 49(3): 419 - 426.
[Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
N. E. Buroker, M. E. Young, C. Wei, K. Serikawa, M. Ge, X.-H. Ning, and M. A. Portman
The dominant negative thyroid hormone receptor beta-mutant {Delta}337T alters PPAR{alpha} signaling in heart
Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E453 - E460.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Sharma, I. C. Okere, M. K. Duda, D. J. Chess, K. M. O'Shea, and W. C. Stanley
Potential impact of carbohydrate and fat intake on pathological left ventricular hypertrophy
Cardiovasc Res, January 15, 2007; 73(2): 257 - 268.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. J. Gilde, J.-C. Fruchart, and B. Staels
Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A24 - A32.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
M. B. Oleksiewicz, I. Thorup, H. S. Nielsen, H. V. Andersen, A. C. Hegelund, L. Iversen, T. S. Guldberg, P. R. Brinck, I. Sjogren, U. K. Thinggaard, et al.
Generalized Cellular Hypertrophy is Induced by a Dual-Acting PPAR Agonist in Rat Urinary Bladder Urothelium In Vivo
Toxicol Pathol, August 1, 2005; 33(5): 552 - 560.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Planavila, R. Rodriguez-Calvo, M. Jove, L. Michalik, W. Wahli, J. C. Laguna, and M. Vazquez-Carrera
Peroxisome proliferator-activated receptor {beta}/{delta} activation inhibits hypertrophy in neonatal rat cardiomyocytes
Cardiovasc Res, March 1, 2005; 65(4): 832 - 841.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. M. Huss and D. P. Kelly
Nuclear Receptor Signaling and Cardiac Energetics
Circ. Res., September 17, 2004; 95(6): 568 - 578.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. E Hardt and J. Sadoshima
Negative regulators of cardiac hypertrophy
Cardiovasc Res, August 15, 2004; 63(3): 500 - 509.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
N. Marx, H. Duez, J.-C. Fruchart, and B. Staels
Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells
Circ. Res., May 14, 2004; 94(9): 1168 - 1178.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. D. I. Anderson, F. Wang, and D. G. Gardner
Role of the Epidermal Growth Factor Receptor in Signaling Strain-dependent Activation of the Brain Natriuretic Peptide Gene
J. Biol. Chem., March 5, 2004; 279(10): 9287 - 9297.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society